Neon Therapeutics (NASDAQ:NTGN) had its target price dropped by stock analysts at Mizuho from $21.00 to $7.00 in a report released on Wednesday, MarketBeat reports. The firm currently has a “buy” rating on the stock. Mizuho’s price objective points to a potential upside of 396.45% from the stock’s current price.

NTGN has been the topic of several other research reports. Bank of America downgraded Neon Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 13th. Zacks Investment Research upgraded Neon Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a research note on Saturday, October 12th. Robert W. Baird initiated coverage on Neon Therapeutics in a research note on Thursday, July 25th. They issued an “outperform” rating and a $15.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Neon Therapeutics in a research note on Monday, November 11th. Finally, ValuEngine upgraded Neon Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $10.58.

Neon Therapeutics stock opened at $1.41 on Wednesday. The company has a quick ratio of 4.59, a current ratio of 4.59 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $42.22 million, a P/E ratio of -0.25 and a beta of 1.59. The stock’s 50 day moving average is $1.91 and its 200 day moving average is $3.36. Neon Therapeutics has a twelve month low of $1.33 and a twelve month high of $7.51.

Neon Therapeutics (NASDAQ:NTGN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.04). As a group, equities analysts expect that Neon Therapeutics will post -2.55 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC bought a new position in Neon Therapeutics in the 3rd quarter valued at approximately $25,000. FNY Investment Advisers LLC bought a new position in Neon Therapeutics in the 3rd quarter valued at approximately $361,000. Morgan Stanley lifted its position in Neon Therapeutics by 10.8% in the 2nd quarter. Morgan Stanley now owns 40,522 shares of the company’s stock valued at $192,000 after acquiring an additional 3,939 shares in the last quarter. Vanguard Group Inc. lifted its position in Neon Therapeutics by 3.6% in the 2nd quarter. Vanguard Group Inc. now owns 612,398 shares of the company’s stock valued at $2,903,000 after acquiring an additional 21,387 shares in the last quarter. Finally, BlackRock Inc. lifted its position in Neon Therapeutics by 11.6% in the 2nd quarter. BlackRock Inc. now owns 765,850 shares of the company’s stock valued at $3,631,000 after acquiring an additional 79,729 shares in the last quarter. 68.51% of the stock is currently owned by institutional investors and hedge funds.

About Neon Therapeutics

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Read More: When is a capital gain realized?

Analyst Recommendations for Neon Therapeutics (NASDAQ:NTGN)

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.